MFG
REGN icon

Merit Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Merit Financial Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08M Sell
3,333
-2,252
-40% -$1.53M 0.01% 738
2026
Q1 		$4.31M Buy
5,585
+1,572
+39% +$1.2M 0.03% 430
2025
Q4 		$3.1M Buy
4,013
+2,154
+116% +$1.46M 0.02% 493
2025
Q3 		$1.05M Buy
1,859
+1,397
+302% +$790K 0.01% 848
2025
Q2 		$243K Sell
462
-1,167
-72% -$651K ﹤0.01% 1450
2025
Q1 		$1.03M Buy
1,629
+761
+88% +$523K 0.02% 641
2024
Q4 		$618K Buy
868
+71
+9% +$59.6K 0.01% 647
2024
Q3 		$837K Sell
797
-79
-9% -$87.9K 0.02% 458
2024
Q2 		$920K Buy
876
+153
+21% +$148K 0.02% 438
2024
Q1 		$691K Buy
723
+396
+121% +$377K 0.02% 499
2023
Q4 		$287K Sell
327
-379
-54% -$312K 0.01% 636
2023
Q3 		$581K Buy
706
+16
+2% +$12.6K 0.02% 426
2023
Q2 		$495K Buy
690
+332
+93% +$256K 0.02% 473
2023
Q1 		$294K Buy
+358
New +$270K 0.01% 517
2020
Q3 		– Sell
-337
Closed -$210K – 236
2020
Q2 		$210K Buy
+337
New +$191K 0.02% 199

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Merit Financial Group's REGN Position: Q2 2026 in Review

Merit Financial Group reduced its Regeneron Pharmaceuticals (REGN) stake by 40% in Q2 2026, selling an estimated $1.53M and leaving 3,333 shares worth $2.08M. The position accounts for 0.01% of the portfolio, ranked #738.

Merit Financial Group first reported a position in REGN in Q2 2020 and has held it in 15 quarters since. The position peaked at $4.31M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Merit Financial Group held 3,333 shares of Regeneron Pharmaceuticals worth $2.08M as of Q2 2026.
  • Merit Financial Group sold 2,252 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.53M.
  • Regeneron Pharmaceuticals made up 0.01% of Merit Financial Group's portfolio in Q2 2026, its #738 holding.
  • Merit Financial Group first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • Merit Financial Group's Regeneron Pharmaceuticals position peaked at $4.31M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.